

# Contents

## I Basic Principles

1	Introduction	2	5.1	Interaction between Innate and Specific Immunity	20
1.1	Dermatology and the Skin	2	A.	Mechanical Barriers	20
A.	Dermatology	2	B.	Innate Immunity	20
B.	Frequency of Skin Diseases	2	C.	Specific Immunity	20
C.	Functions of the Skin	2	5.2	Organs of the Immune System	22
2	Embryology and Anatomy	4	A.	Organs of the Immune System	22
2.1	Embryology and the Epidermis	4	5.3	Cells of the Immune System: Overview	24
A.	Embryology	4	A.	Development of Immune Cells	24
B.	The Epidermis	4	B.	Antigen-presenting Cells	24
C.	The Basement Membrane Zone	4	C.	Granulocytes and Mast Cells	24
2.2	Adnexal Structures	6	D.	Natural Killer Cells	24
A.	The Adnexal Glands	6	5.4	T Cells	26
B.	Temperature Control	6	A.	T-cell Development and Function	26
2.3	The Dermis	8	B.	Interaction between Antigen-presenting Cells and T Cells	26
A.	The Dermis	8	5.5	T-cell Differentiation: T <sub>H17</sub> and Regulatory T Cells	28
B.	Extracellular Matrix Components	8	A.	T <sub>H17</sub> and Regulatory T Cells	28
2.4	The Hair, Nails, and Subcutaneous Fat	10	B.	T <sub>H17</sub> Cells	28
A.	Hair Development and Structure	10	C.	Regulatory T Cells	28
B.	The Hair Cycle	10	5.6	B Cells	30
C.	Types of Hair	10	A.	Development and Function of B Cells	30
D.	Nail Development and Structure	12	5.7	Important Mediators of the Immune System	32
E.	Subcutaneous Fat	12	A.	Cytokines	32
3	Biochemistry	14	B.	Chemokines	32
3.1	Keratin	14	C.	Surface Molecules	32
A.	Keratinization	14	5.8	Intolerance Reactions	34
B.	Structural Correlates of the Epidermis	14	A.	Immediate Reaction (Type I)	34
C.	Patterns of Keratinization	14	B.	Cytotoxic Reaction (Type II)	34
3.2	Melanin	16	C.	Immune-complex Reaction (Type III)	34
A.	Melanocytes	16	D.	Delayed Reaction (Type IV)	34
B.	Melanogenesis	16	5.9	Type I Reaction: Immediate Hypersensitivity	36
C.	Defects in Melanocytes	16	A.	IgE Production	36
D.	Skin Color and Type	16	B.	Effector Mechanisms: Immediate Phase	36
E.	Approach to Pigmented Lesions	16	C.	Effector Mechanisms: Late Phase, Persistent Inflammation	36
4	Physiology	18	5.10	Type II and Type III Reactions	38
4.1	Cutaneous Sensation	18	A.	Type II Reaction (Immunglobulin-mediated Cytotoxicity)	38
A.	Cutaneous Innervation	18	B.	Type III Reaction (Immune-complex Reaction)	38
B.	The Neuronal Basis of Pruritus	18			
C.	Sympathetic Nerves	18			
5	Immunology	20			

<b>5.11 Type IV Reaction (Delayed-type Hypersensitivity Reaction) . . . . .</b>	<b>40</b>	<b>6 Genetics . . . . .</b>	<b>44</b>
A. Type IV Reaction . . . . .	40	<b>6.1 Genetics . . . . .</b>	<b>44</b>
B. CD4+ T-cell-mediated Immune Reaction . . . . .	40	A. Genodermatoses . . . . .	44
C. CD8+ Immune Reaction . . . . .	42	B. Patterns of Inheritance . . . . .	44
		C. Uses of Genetics . . . . .	44

## II Diagnosis of Dermatologic Diseases

<b>7 Laboratory . . . . .</b>	<b>48</b>	<b>8 In-vivo Allergy Diagnosis . . . . .</b>	<b>58</b>
<b>7.1 In-vitro Diagnosis of Allergy . . . . .</b>	<b>48</b>	<b>8.1 Overview of Allergy Testing . . . . .</b>	<b>58</b>
A. Definition and Indications . . . . .	48	A. Requirements for Allergy Testing . .	58
B. Test Procedures . . . . .	48	B. Exogenous Influences . . . . .	58
C. Cellular Allergen Stimulation Test .	48	<b>8.2 Physical Testing . . . . .</b>	<b>60</b>
D. Eosinophilic Cationic Protein and Trypsase . . . . .	48	A. Choice of Test Methods . . . . .	60
<b>7.2 Histopathology . . . . .</b>	<b>50</b>	B. Physical Urticaria . . . . .	60
A. Biopsy Techniques . . . . .	50	<b>8.3 Skin Tests I . . . . .</b>	<b>62</b>
B. Staining Techniques . . . . .	50	A. Skin Tests . . . . .	62
C. Histological Features . . . . .	52	B. Tuberculin Test . . . . .	62
D. Patterns of Inflammation . . . . .	52	<b>8.4 Skin Tests II . . . . .</b>	<b>64</b>
E. Approach to Slides . . . . .	52	A. Patch Testing . . . . .	64
<b>7.3 Immunofluorescence and Electron Microscopy . . . . .</b>	<b>54</b>	B. Test Substances . . . . .	64
A. Types of Examination . . . . .	54	C. Special Situations and Test Modifications . . . . .	64
B. Technical Tips . . . . .	54	<b>9 Imaging Procedures . . . . .</b>	<b>66</b>
C. Examples of Uses . . . . .	54	<b>9.1 Dermatoscopy . . . . .</b>	<b>66</b>
D. Advanced Techniques . . . . .	54	A. Dermatoscopy . . . . .	66
E. Electron Microscopy . . . . .	54	B. Digital Dermatoscopy . . . . .	68
<b>7.4 Mycology and Bacteriology . . . . .</b>	<b>56</b>	<b>9.2 Sonography . . . . .</b>	<b>70</b>
A. Mycological Diagnosis . . . . .	56	A. Sonography . . . . .	70
B. Bacteriologic Diagnosis . . . . .	56	B. Other Imaging Procedures . . . . .	70

## III Treatment of Dermatologic Diseases

<b>10 Medical Therapy . . . . .</b>	<b>74</b>	<b>10.4 Biologicals . . . . .</b>	<b>82</b>
<b>10.1 Principles of Topical Therapy . . . . .</b>	<b>74</b>	A. Definition . . . . .	82
A. Interactions between Medications and Skin . . . . .	74	B. Anti-TNF Therapy . . . . .	82
B. Vehicles . . . . .	74	C. Anti-IL-12/IL-23p40 Therapy . . . . .	82
C. Compounding . . . . .	74	D. New Compounds . . . . .	82
D. Tricks for Topical Prescribing . . . . .	74	<b>10.5 Cytokines, Toll-like Receptor Agonists . . . . .</b>	<b>84</b>
<b>10.2 Corticosteroids . . . . .</b>	<b>76</b>	A. Immunostimulators . . . . .	84
A. Structure and Potency . . . . .	76	B. Interleukin 2 . . . . .	84
B. Mechanisms of Action . . . . .	76	C. Interleukin 12 . . . . .	84
C. Indications and Side Effects . . . . .	78	D. Interferons . . . . .	84
<b>10.3 Calcineurin Inhibitors, Azathioprine, and Mycophenolate Mofetil . . . . .</b>	<b>80</b>	E. Toll-like Receptor Agonists . . . . .	84
A. Calcineurin Inhibitors . . . . .	80	F. CTLA-4 Antagonists . . . . .	84
B. Azathioprine . . . . .	80	<b>10.6 Thalidomide, Chloroquine, and Fumaric Acid Esters . . . . .</b>	<b>86</b>
C. Mycophenolate Mofetil . . . . .	80	A. Thalidomide . . . . .	86
		B. Chloroquine . . . . .	86
		C. Fumaric Acid Esters . . . . .	86

<b>10.7 Nonsteroidal Anti-inflammatory Agents and Dapsone</b> . . . . .	<b>88</b>	<b>10.16 Miscellaneous Topical Agents</b> . . . . .	<b>116</b>
A. Nonsteroidal Anti-inflammatory Agents . . . . .	88	A. Antiperspirants . . . . .	116
B. Dapsone . . . . .	88	B. Medications for Disturbances of Pigmentation . . . . .	116
<b>10.8 Cytostatic Agents</b> . . . . .	<b>90</b>	C. Skin Cleansers and Protective Agents . . . . .	116
A. Indirect Inhibition of DNA Function . . . . .	90	<b>11 Physical Modes of Therapy</b> . . . . .	<b>118</b>
B. Direct DNA Interactions . . . . .	92	<b>11.1 Phototherapy</b> . . . . .	<b>118</b>
C. Molecular Therapy . . . . .	92	A. Ultraviolet Radiation . . . . .	118
D. Topical Use . . . . .	92	B. Principles of Phototherapy . . . . .	118
<b>10.9 Antibacterial Agents</b> . . . . .	<b>94</b>	C. UVB Phototherapy . . . . .	118
A. Patient-Bacteria Interactions . . . . .	94	D. UVA and UVA <sub>1</sub> Phototherapy . . . . .	120
B. Site of Action . . . . .	94	E. Photochemotherapy . . . . .	120
C. Mechanisms of Action and Resistance . . . . .	94	<b>11.2 Photodynamic Therapy, Radiation Therapy, and Cryotherapy</b> . . . . .	<b>122</b>
D. Classes of Antibiotics . . . . .	94	A. Photodynamic Therapy . . . . .	122
E. Topical Antibiotics . . . . .	100	B. Radiation Therapy . . . . .	122
F. Disinfectants . . . . .	100	C. Cryotherapy . . . . .	122
<b>10.10 Antimycotic Agents</b> . . . . .	<b>102</b>	<b>11.3 Laser Therapy</b> . . . . .	<b>124</b>
A. Inhibitors of Ergosterol Synthesis . . . . .	102	A. Principles of Laser Therapy . . . . .	124
B. Pyridones . . . . .	102	B. Nonspecific Coagulation . . . . .	124
C. Inhibitors of Cell Wall or DNA Synthesis . . . . .	102	C. Semi-selective Lasers . . . . .	124
D. Polyene Antibiotics . . . . .	102	D. Selective Photothermolysis . . . . .	124
<b>10.11 Antiviral Agents</b> . . . . .	<b>104</b>	E. Vaporization and Ablation . . . . .	124
A. Mechanisms of Action . . . . .	104	F. Intense Pulsed Light . . . . .	124
B. Antiviral Agents in HIV/AIDS . . . . .	106	<b>12 Operative Dermatology</b> . . . . .	<b>126</b>
<b>10.12 Antiparasitic Agents</b> . . . . .	<b>108</b>	<b>12.1 General Aspects and Techniques</b> . . . . .	<b>126</b>
A. Acaricides/Insecticides . . . . .	108	A. General Aspects . . . . .	126
B. Repellents . . . . .	108	B. Operative Techniques . . . . .	126
C. Anthelmintic Agents . . . . .	108	<b>12.2 Aesthetic Dermatology</b> . . . . .	<b>130</b>
<b>10.13 Retinoids</b> . . . . .	<b>110</b>	A. Botulinum Toxin A . . . . .	130
<b>10.14 Antihistamines and Antipruritic Agents</b> . . . . .	<b>112</b>	B. Fillers . . . . .	130
A. Antihistamines . . . . .	112	C. Peeling . . . . .	130
B. Antipruritic Agents . . . . .	112	D. Laser Skin Resurfacing . . . . .	130
<b>10.15 Keratolytics and Antiproliferative Agents</b> . . . . .	<b>114</b>	E. Dermabrasion . . . . .	132
A. Keratolytics . . . . .	114	F. Lip Augmentation . . . . .	132
B. Antiproliferative Agents . . . . .	114	G. Lifting . . . . .	132
		H. Thermal Lifting . . . . .	132
		I. Liposuction . . . . .	132
		J. Cosmetic Vein Surgery . . . . .	132
		K. Plastic-reconstructive Surgery . . . . .	132

## IV Dermatologic Diseases

<b>13 Dermatologic Examination</b> . . . . .	<b>136</b>	<b>13.2 Types of Lesions</b> . . . . .	<b>138</b>
<b>13.1 History and Symptoms</b> . . . . .	<b>136</b>	A. Primary Lesions . . . . .	138
A. History . . . . .	136	B. Secondary Lesions . . . . .	138
B. Symptoms . . . . .	136	C. Features of Lesions . . . . .	138
C. Signs (Physical Findings) . . . . .	136		

<b>13.3 Erythroderma</b> .....	<b>140</b>	<b>14.8 Lichen Planus</b> .....	<b>162</b>
A. Definition .....	140	A. Pathogenesis .....	162
B. Pathophysiology .....	140	B. Clinical Features .....	162
C. Etiology .....	140	C. Histology .....	162
D. Clinical Features .....	140	D. Differential Diagnosis .....	162
E. Diagnostic Approach .....	140	E. Course .....	162
F. Therapy .....	140	F. Therapy .....	162
		G. Variants .....	162
<b>14 Inflammatory Diseases of the Epidermis</b> .....	<b>142</b>	<b>14.9 Graft Versus Host Disease</b> .....	<b>164</b>
<b>14.1 Dermatitis and Eczema</b> .....	<b>142</b>	A. Pathogenesis .....	164
A. Epidemiology .....	142	B. Clinical Features .....	164
B. Clinical Features .....	142	C. Histopathology .....	164
C. Histopathology .....	142	D. Course .....	164
D. Differential Diagnosis .....	142	E. Therapy .....	164
E. Therapy .....	142		
<b>14.2 Allergic Contact Dermatitis</b> .....	<b>144</b>	<b>14.10 Pruritus and Prurigo</b> .....	<b>166</b>
A. Definition .....	144	A. Pruritus .....	166
B. Epidemiology .....	144	B. Localized Pruritus .....	166
C. Pathogenesis .....	144	C. Prurigo .....	166
D. Clinical Features .....	144	D. Therapy .....	166
E. Diagnosis and Therapy .....	144		
<b>14.3 Irritant Contact Dermatitis and Other Types of Dermatitis</b> .....	<b>146</b>	<b>14.11 Pemphigus</b> .....	<b>168</b>
A. Definition .....	146	A. Epidemiology .....	168
B. Epidemiology .....	146	B. Pathogenesis .....	168
C. Pathogenesis .....	146	C. Clinical Features .....	168
D. Clinical Features .....	146	D. Histopathology and Immunofluorescence .....	168
E. Therapy .....	146	E. Course .....	168
F. Other Types of Dermatitis .....	146	F. Therapy .....	168
<b>14.4 Atopic Dermatitis, Allergic Rhinitis, and Asthma</b> .....	<b>148</b>	<b>15 Inflammatory Diseases of the Dermal–Epidermal Junction</b> .....	<b>170</b>
A. Atopic Dermatitis .....	148	<b>15.1 Pemphigoid Diseases and Dermatitis Herpetiformis</b> .....	<b>170</b>
B. Allergic Rhinoconjunctivitis .....	150	A. Pathogenesis .....	170
C. Asthma .....	152	B. Clinical Features .....	170
		C. Histopathology and Immunofluorescence .....	172
<b>14.5 Psoriasis</b> .....	<b>154</b>	D. Course .....	172
A. Epidemiology and Subtypes .....	154	E. Therapy .....	172
B. Pathogenesis .....	154	F. Dermatitis Herpetiformis .....	172
C. Histopathology .....	154		
D. Clinical Features .....	154	<b>16 Genetic Diseases of the Dermal–Epidermal Junction</b> .....	<b>174</b>
E. Course .....	156	<b>16.1 Epidermolysis Bullosa</b> .....	<b>174</b>
F. Therapy .....	156	A. Definition .....	174
<b>14.6 Seborrheic Dermatitis and Reactive Arthritis</b> .....	<b>158</b>	B. Pathogenesis .....	174
A. Seborrheic Dermatitis .....	158	C. Clinical Features .....	174
B. Reactive Arthritis .....	158	D. Therapy .....	174
<b>14.7 Pityriasis Lichenoides, Pityriasis Rosea, and Pityriasis Rubra Pilaris</b> .....	<b>160</b>		
A. Pityriasis Lichenoides .....	160		
B. Pityriasis Rosea .....	160		
C. Pityriasis Rubra Pilaris .....	161		

<b>17</b>	<b>Inflammatory Diseases of the Dermis</b> . . . . .	<b>176</b>	<b>18</b>	<b>Inflammatory Diseases of the Subcutaneous Fat</b> . . . . .	<b>198</b>
<b>17.1</b>	<b>Urticaria, Angioedema, and Anaphylaxis</b> . . . . .	<b>176</b>	<b>18.1</b>	<b>Panniculitis</b> . . . . .	<b>198</b>
A.	Pathogenesis . . . . .	176	A.	Overview . . . . .	198
B.	Clinical Features . . . . .	176	B.	Clinical Types . . . . .	198
C.	Histopathology . . . . .	178	C.	Lipoatrophy and Lipodystrophy . . . . .	198
D.	Diagnostic Approach . . . . .	178	<b>19</b>	<b>Genetic Diseases of the Connective Tissue</b> . . . . .	<b>200</b>
E.	Therapy . . . . .	178	<b>19.1</b>	<b>Disorders of Collagen and Elastin</b> . . . . .	<b>200</b>
<b>17.2</b>	<b>Erythema Multiforme, Figurate Erythemas, and Nodose Erythemas</b> . . . . .	<b>180</b>	A.	Ehlers–Danlos Syndrome . . . . .	200
A.	Erythema Multiforme . . . . .	180	B.	Marfan Syndrome . . . . .	200
B.	Figurate Erythemas . . . . .	180	C.	Cutis Laxa . . . . .	200
C.	Nodose Erythemas . . . . .	180	D.	Pseudoxanthoma Elasticum . . . . .	200
<b>17.3</b>	<b>Dermatomyositis</b> . . . . .	<b>182</b>	<b>20</b>	<b>Genetic Diseases of the Epidermis</b> . . . . .	<b>202</b>
A.	Pathogenesis . . . . .	182	<b>20.1</b>	<b>Disorders of Keratinization</b> . . . . .	<b>202</b>
B.	Clinical Features . . . . .	182	A.	Ichthyoses . . . . .	202
C.	Histopathology . . . . .	182	B.	Palmoplantar Keratodermas . . . . .	202
D.	Differential Diagnosis . . . . .	182	C.	Dyskeratotic-acantholytic Disorders . . . . .	204
E.	Course . . . . .	182	D.	Follicular Keratoses . . . . .	204
F.	Therapy . . . . .	182	E.	Porokeratoses . . . . .	204
<b>17.4</b>	<b>Systemic Sclerosis, Morphea, and Lichen Sclerosus et Atrophicus</b> . . . . .	<b>184</b>	F.	Erythrokeratodermas . . . . .	205
A.	Systemic Sclerosis . . . . .	184	<b>20.2</b>	<b>Mosaicism</b> . . . . .	<b>206</b>
B.	Morphea . . . . .	186	A.	Mosaicism . . . . .	206
C.	Lichen Sclerosus et Atrophicus . . . . .	186	B.	Epigenetic Mosaicism . . . . .	206
<b>17.5</b>	<b>Lupus Erythematosus</b> . . . . .	<b>188</b>	C.	Genomic Mosaicism . . . . .	206
A.	Chronic Cutaneous or Discoid Lupus Erythematosus . . . . .	188	D.	Acquired Dermatoses in Blaschko Lines . . . . .	206
B.	Subacute Cutaneous Lupus Erythematosus . . . . .	188	<b>20.3</b>	<b>Epidermal Nevi</b> . . . . .	<b>208</b>
C.	Systemic Lupus Erythematosus . . . . .	190	A.	Epidermal Nevi . . . . .	208
D.	Course . . . . .	190	B.	Special Types . . . . .	208
E.	Therapy . . . . .	190	C.	Epidermal Nevus Syndromes . . . . .	208
<b>17.6</b>	<b>Diseases with Eosinophilia</b> . . . . .	<b>192</b>	D.	Solitary Lesions . . . . .	208
A.	Hypereosinophilic Syndrome . . . . .	192	<b>21</b>	<b>Tumors of the Epidermis</b> . . . . .	<b>210</b>
B.	Eosinophilic Cellulitis . . . . .	192	<b>21.1</b>	<b>Benign Epidermal Tumors</b> . . . . .	<b>210</b>
C.	Eosinophilic Fasciitis . . . . .	192	A.	Seborrheic Keratosis . . . . .	210
D.	Granuloma Faciale . . . . .	192	B.	Acanthosis Nigricans . . . . .	210
E.	Eosinophilic Pustular Folliculitis . . . . .	192	C.	Confluent and Reticulated Papillomatosis (Gougerot–Carteaud Disease) . . . . .	210
<b>17.7</b>	<b>Noninfectious Granulomatous Diseases</b> . . . . .	<b>194</b>	D.	Clear Cell Acanthoma . . . . .	210
A.	Sarcoidosis . . . . .	194	<b>21.2</b>	<b>Cysts and Adnexal Tumors</b> . . . . .	<b>212</b>
B.	Granuloma Annulare . . . . .	196	A.	Cysts . . . . .	212
C.	Necrobiosis Lipoidica . . . . .	196	B.	Adnexal Tumors . . . . .	212
D.	Rheumatoid Nodule . . . . .	196	<b>21.3</b>	<b>Malignant Adnexal Tumors and Paget Disease</b> . . . . .	<b>214</b>
E.	Foreign Body Granuloma . . . . .	197	A.	Malignant Adnexal Tumors . . . . .	214
			B.	Paget Disease . . . . .	214
			C.	Extramammary Paget Disease . . . . .	215

<b>21.4 Basal Cell Carcinoma . . . . .</b>	<b>216</b>	<b>23 Hematopoietic Tumors . . . . .</b>	<b>240</b>
A. Basal Cell Carcinoma . . . . .	216	<b>23.1 Cutaneous Lymphomas . . . . .</b>	<b>240</b>
B. Nevoid Basal Cell Carcinoma Syn- drome (Gorlin–Goltz syndrome) . .	218	A. Definition and Classification . . . . .	240
<b>21.5 Squamous Cell Carcinoma and Metastases . . . . .</b>	<b>220</b>	B. Epidemiology . . . . .	240
A. Carcinomata In Situ . . . . .	220	C. Pathogenesis . . . . .	240
B. Squamous Cell Carcinoma . . . . .	222	D. Parapsoriasis . . . . .	240
C. Variants of Squamous Cell Carcinoma . . . . .	224	E. Mycosis Fungoides . . . . .	240
D. Skin Metastases . . . . .	224	F. Sézary Syndrome . . . . .	242
<b>22 Tumors of the Dermis and Subcutis . . . . .</b>	<b>226</b>	G. Other Cutaneous T-cell Lymphomas . . . . .	242
<b>22.1 Benign Tumors of Fat and Connective Tissue . . . . .</b>	<b>226</b>	H. Cutaneous B-cell Lymphomas . . . . .	242
A. Benign Tumors of Fat . . . . .	226	I. Pseudolymphoma . . . . .	242
B. Benign Tumors of Connective Tissue . . . . .	226	<b>23.2 Mast Cell Disorders . . . . .</b>	<b>244</b>
<b>22.2 Other Benign Soft-tissue Tumors .</b>	<b>228</b>	A. Introduction . . . . .	244
A. Leiomyoma . . . . .	228	B. Mastocytoma . . . . .	244
B. Rhabdomyoma . . . . .	228	C. Urticaria Pigmentosa . . . . .	244
C. Osteoma . . . . .	228	D. Telangiectasia Macularis Eruptive Perstans . . . . .	244
D. Chondroma . . . . .	228	E. Systemic Mastocytosis . . . . .	244
<b>22.3 Soft-tissue Sarcomas . . . . .</b>	<b>230</b>	<b>23.3 Histiocytoses and Leukemia . . . . .</b>	<b>246</b>
A. Dermatofibrosarcoma Protuberans . . . . .	230	A. Langerhans Cell Disease . . . . .	246
B. Other Cutaneous Sarcomas . . . . .	230	B. Sinus Histiocytosis with Massive Lymphadenopathy . . . . .	246
<b>22.4 Vascular Malformations . . . . .</b>	<b>232</b>	C. Juvenile Xanthogranuloma . . . . .	248
A. Capillary Malformations . . . . .	232	D. Other Macrophage Disorders . . . . .	248
B. Venous Malformations . . . . .	232	E. Leukemia . . . . .	248
C. Lymphatic Malformations . . . . .	232	<b>24 Disorders of Melanocytes and Pigmentation . . . . .</b>	<b>250</b>
D. Arteriovenous Malformations . . . . .	232	<b>24.1 Vitiligo and Albinism . . . . .</b>	<b>250</b>
E. Therapy . . . . .	232	A. Vitiligo . . . . .	250
F. Acroangiodermatitis . . . . .	232	B. Albinism . . . . .	250
G. Glomus Tumor . . . . .	232	C. Piebaldism . . . . .	251
<b>22.5 Hemangiomas and Other Benign Vascular Tumors . . . . .</b>	<b>234</b>	<b>24.2 Melanotic Spots and Melanocytic Nevi . . . . .</b>	<b>252</b>
A. Infantile Hemangioma . . . . .	234	A. Melanotic Spots . . . . .	252
B. Pyogenic Granuloma . . . . .	234	B. Melanocytic Nevi . . . . .	252
C. Eruptive Angioma . . . . .	235	<b>24.3 Melanoma . . . . .</b>	<b>256</b>
<b>22.6 Malignant and Other Vascular Tumors . . . . .</b>	<b>236</b>	A. Definition . . . . .	256
A. Kaposi Sarcoma . . . . .	236	B. Epidemiology . . . . .	256
B. Angiosarcoma . . . . .	236	C. Pathogenesis . . . . .	256
C. Other Vascular Tumors . . . . .	236	D. Clinical Features . . . . .	256
<b>22.7 Neural Tumors . . . . .</b>	<b>238</b>	E. Histopathology . . . . .	258
A. Benign Neural Tumors . . . . .	238	F. Differential Diagnosis . . . . .	258
B. Merkel Cell Carcinoma . . . . .	238	G. Diagnostic Approach . . . . .	258
		H. Prognosis . . . . .	258
		I. Therapy . . . . .	260

<b>25</b>	<b>Diseases of the Vascular System . . .</b>	<b>262</b>	<b>27</b>	<b>Cutaneous Signs of Systemic Diseases . . . . .</b>	<b>282</b>
<b>25.1</b>	<b>Vasculitis and Purpura . . . . .</b>	<b>262</b>	<b>27.1</b>	<b>Amyloidosis and Hyalinosis . . . . .</b>	<b>282</b>
A.	Definition . . . . .	262	A.	Pathogenesis . . . . .	282
B.	Classification . . . . .	262	B.	Systemic Amyloidosis . . . . .	282
C.	Large-vessel Vasculitis . . . . .	262	C.	Cutaneous Amyloidosis . . . . .	282
D.	Mid-sized-vessel Vasculitis . . . . .	262	D.	Hyalinosis . . . . .	282
E.	Small-vessel Vasculitis . . . . .	262	<b>27.2</b>	<b>Diabetes Mellitus . . . . .</b>	<b>284</b>
F.	Leukocytoclastic Vasculitis . . . . .	262	A.	Overview . . . . .	284
G.	Therapy . . . . .	264	B.	Cutaneous Infections . . . . .	284
H.	Septic Vasculitis . . . . .	264	C.	Diabetes-associated Dermatoses . . . . .	284
I.	Thromboangiitis Obliterans . . . . .	264	D.	Diabetic Neurovascular Disease . . . . .	284
J.	Purpura . . . . .	264	E.	Complications of Therapy . . . . .	284
K.	Pigmented Purpuric Dermatoses . . . . .	264	<b>27.3</b>	<b>Endocrine Disorders . . . . .</b>	<b>286</b>
L.	Antiphospholipid Syndrome . . . . .	266	A.	Pituitary Gland . . . . .	286
M.	Livedo Vasculitis . . . . .	266	B.	Thyroid Gland . . . . .	286
N.	Pyoderma Gangrenosum . . . . .	266	C.	Parathyroid Glands . . . . .	286
O.	Behçet Disease . . . . .	266	D.	Adrenal Glands . . . . .	286
<b>25.2</b>	<b>Diseases of Veins . . . . .</b>	<b>268</b>	E.	Pancreas . . . . .	286
A.	Anatomy and Physiology . . . . .	268	F.	Polyendocrine Diseases . . . . .	286
B.	Chronic Venous Insufficiency . . . . .	268	<b>27.4</b>	<b>Gammopathies and Cryoglobulinemia . . . . .</b>	<b>288</b>
C.	Thrombophlebitis . . . . .	270	A.	Gammopathy . . . . .	288
D.	Deep Vein Thrombosis . . . . .	270	B.	Clinical Disorders . . . . .	288
<b>26</b>	<b>Diseases of Adnexal Structures . . .</b>	<b>272</b>	C.	Gammopathy-associated Diseases . . . . .	288
<b>26.1</b>	<b>Acne . . . . .</b>	<b>272</b>	<b>27.5</b>	<b>Hepatic and Renal Diseases . . . . .</b>	<b>290</b>
A.	Epidemiology and Pathogenesis . . . . .	272	A.	Cutaneous Signs of Hepatic Disease . . . . .	290
B.	Clinical Features . . . . .	272	B.	Cutaneous Signs of Specific Liver Diseases . . . . .	290
C.	Therapy . . . . .	272	C.	Cutaneous Signs of Renal Failure/ Dialysis . . . . .	290
<b>26.2</b>	<b>Rosacea . . . . .</b>	<b>274</b>	D.	Cutaneous Diseases with Renal Involvement . . . . .	290
A.	Epidemiology and Pathogenesis . . . . .	274	<b>27.6</b>	<b>Gastrointestinal Diseases . . . . .</b>	<b>292</b>
B.	Clinical Features . . . . .	274	A.	Cutaneous Signs of Gastrointestinal Disease . . . . .	292
C.	Therapy . . . . .	274	B.	Cutaneous Signs of Gastrointestinal Malignancy . . . . .	292
<b>26.3</b>	<b>Diseases of the Sweat Glands . . . .</b>	<b>276</b>	C.	Inflammatory Bowel Disease . . . . .	292
A.	Primary Hyperhidrosis . . . . .	276	<b>27.7</b>	<b>Metabolic Diseases . . . . .</b>	<b>294</b>
B.	Secondary Hyperhidrosis . . . . .	276	A.	Disorders of Lipid Metabolism . . . . .	294
C.	Hypohidrosis and Anhidrosis . . . . .	276	B.	Gout . . . . .	294
D.	Chromhidrosis and Bromhidrosis . . . . .	276	C.	Hemochromatosis . . . . .	294
E.	Inflammatory Diseases . . . . .	276	D.	Calcification . . . . .	294
<b>26.4</b>	<b>Diseases of the Hair . . . . .</b>	<b>278</b>	E.	Fabry Disease . . . . .	294
A.	Alopecia . . . . .	278	<b>27.8</b>	<b>Neurologic Diseases . . . . .</b>	<b>296</b>
B.	Hair Shaft Anomalies . . . . .	278	A.	Neuropathic Skin Damage . . . . .	296
C.	Hypo- and Hypertrichosis . . . . .	278	B.	Neurocutaneous Diseases . . . . .	296
D.	Hirsutism . . . . .	278	<b>27.9</b>	<b>Paraneoplastic Disorders . . . . .</b>	<b>298</b>
<b>26.5</b>	<b>Diseases of the Nails . . . . .</b>	<b>280</b>	A.	Cutaneous Signs of Internal Malignancy . . . . .	298
A.	Changes in the Nail Plate . . . . .	280	B.	Obligate Paraneoplastic Markers . . . . .	298
B.	Changes in Nail Color . . . . .	280	C.	Possible Paraneoplastic Markers . . . . .	298
C.	Genetic Nail Anomalies . . . . .	280			
D.	Tumors of Nail Region . . . . .	280			

<b>28</b>	<b>Skin Diseases in Different Stages of Life</b> . . . . .	<b>300</b>	<b>32.3</b>	<b>Other Viruses</b> . . . . .	<b>324</b>
<b>28.1</b>	<b>Skin Diseases in Infancy</b> . . . . .	<b>300</b>	A.	Pox Viruses . . . . .	324
A.	Unique Features of Infantile Skin . . . . .	300	B.	Picornia Viruses . . . . .	324
B.	Skin Diseases in Infancy . . . . .	300	C.	Classic Viral Infections of Childhood . . . . .	326
<b>28.2</b>	<b>Skin Diseases during Pregnancy</b> . . . . .	<b>302</b>	D.	Other Viral Exanthems . . . . .	326
A.	Physiologic Skin Changes . . . . .	302	<b>33</b>	<b>Bacterial Diseases</b> . . . . .	<b>328</b>
B.	Dermatoses of Pregnancy . . . . .	302	<b>33.1</b>	<b>Staphylococci and Streptococci</b> . . . . .	<b>328</b>
C.	Infections in Pregnancy . . . . .	302	A.	Impetigo . . . . .	328
<b>28.3</b>	<b>Skin Diseases in the Elderly</b> . . . . .	<b>304</b>	B.	Folliculitis, Furuncle, and Carbuncle . . . . .	328
A.	Skin Aging . . . . .	304	C.	Staphylococcal Scalded Skin Syndrome . . . . .	328
B.	Features of Aging Skin . . . . .	304	D.	Erysipelas . . . . .	328
C.	Diseases of Aging Skin . . . . .	304	E.	Other Deep Infections . . . . .	330
<b>29</b>	<b>Adverse Drug Reactions</b> . . . . .	<b>306</b>	F.	Other Infections . . . . .	330
<b>29.1</b>	<b>Adverse Drug Reactions</b> . . . . .	<b>306</b>	G.	Toxic Shock Syndromes . . . . .	330
A.	Overview . . . . .	306	H.	Scarlet Fever . . . . .	330
B.	Severe Skin Reactions . . . . .	306	<b>33.2</b>	<b>Corynebacteria and Other Gram-positive Bacteria</b> . . . . .	<b>332</b>
C.	Classic Drug Reactions . . . . .	306	A.	Corynebacteria . . . . .	332
D.	Unique Drug Reactions . . . . .	308	B.	Other Gram-positive Bacteria . . . . .	332
<b>30</b>	<b>Genodermatoses</b> . . . . .	<b>310</b>	<b>33.3</b>	<b>Gram-negative Bacteria and Bites</b> . . . . .	<b>334</b>
<b>30.1</b>	<b>Neurocutaneous Genodermatoses</b> . . . . .	<b>310</b>	A.	Gram-negative Folliculitis . . . . .	334
A.	Neurofibromatosis . . . . .	310	B.	Whirlpool Dermatitis . . . . .	334
B.	Tuberous Sclerosis . . . . .	310	C.	Gram-negative Toe-web Infection . . . . .	334
C.	Ataxia-telangiectasia . . . . .	311	D.	Cat Scratch Disease . . . . .	334
<b>30.2</b>	<b>Light-sensitive Genodermatoses</b> . . . . .	<b>312</b>	E.	Yersiniosis . . . . .	334
A.	Porphyria . . . . .	312	F.	Clostridia Infections . . . . .	334
B.	Xeroderma Pigmentosum . . . . .	312	G.	Bite Injuries . . . . .	334
<b>30.3</b>	<b>Cancer-associated Genodermatoses</b> . . . . .	<b>314</b>	<b>33.4</b>	<b>Borrelia and Other Spirochetes</b> . . . . .	<b>336</b>
A.	Cancer-associated Syndromes . . . . .	314	A.	Lyme Borreliosis . . . . .	336
<b>31</b>	<b>Psychocutaneous Diseases</b> . . . . .	<b>316</b>	B.	Other Spirochetal Infections . . . . .	336
<b>31.1</b>	<b>Psychocutaneous Diseases</b> . . . . .	<b>316</b>	<b>33.5</b>	<b>Mycobacteria</b> . . . . .	<b>338</b>
A.	Primary Psychiatric Disorders . . . . .	316	A.	Skin Tuberculosis in Anergic Patients . . . . .	338
B.	Psychosomatic Disorders . . . . .	316	B.	Skin Tuberculosis in Patients with Normal Resistance . . . . .	338
C.	Secondary Psychiatric Disorders . . . . .	316	C.	Leprosy . . . . .	338
<b>32</b>	<b>Viral Diseases</b> . . . . .	<b>318</b>	D.	Atypical Mycobacteria . . . . .	340
<b>32.1</b>	<b>Human Papillomaviruses</b> . . . . .	<b>318</b>	<b>34</b>	<b>Fungal Diseases</b> . . . . .	<b>342</b>
A.	Clinical Features . . . . .	318	<b>34.1</b>	<b>Dermatophytes</b> . . . . .	<b>342</b>
B.	Therapy . . . . .	318	A.	Tinea Capitis . . . . .	342
<b>32.2</b>	<b>Human Herpes Viruses</b> . . . . .	<b>320</b>	B.	Tinea Barbae . . . . .	342
A.	Herpes Simplex Virus . . . . .	320	C.	Tinea Pedis and Manus . . . . .	342
B.	Varicella Zoster Virus . . . . .	320	D.	Tinea Corporis and Faciei . . . . .	344
C.	Epstein-Barr Virus . . . . .	322	E.	Tinea Inguinalis . . . . .	344
D.	Cytomegalovirus Virus . . . . .	322	F.	Tinea Unguium . . . . .	344
E.	Human Herpes Virus 6 . . . . .	322	G.	Special Variants . . . . .	344
F.	Human Herpesvirus 8 . . . . .	322			



<b>34.2 Yeasts</b> . . . . .	<b>346</b>	D. Syphilis in HIV. . . . .	364
A. Malassezia . . . . .	346	E. Diagnostic Approach . . . . .	366
B. Candida . . . . .	346	F. Therapy . . . . .	366
C. Therapy . . . . .	348	<b>36.3 Other Venereal Diseases</b> . . . . .	<b>368</b>
<b>34.3 Subcutaneous and Systemic Mycoses</b> . . . . .	<b>350</b>	A. Lymphogranuloma Venereum . . . . .	368
A. Subcutaneous Mycoses . . . . .	350	B. Chancroid . . . . .	368
B. Systemic Mycoses . . . . .	350	C. Granuloma Inguinale . . . . .	368
<b>35 Parasitic Diseases</b> . . . . .	<b>352</b>	<b>37 HIV/AIDS</b> . . . . .	<b>370</b>
<b>35.1 Protozoa</b> . . . . .	<b>352</b>	<b>37.1 HIV/AIDS</b> . . . . .	<b>370</b>
A. Leishmaniasis . . . . .	352	A. Epidemiology . . . . .	370
B. Trichomoniasis . . . . .	352	B. Pathogenesis . . . . .	370
C. Amebiasis . . . . .	352	C. Clinical Classification . . . . .	370
<b>35.2 Worms</b> . . . . .	<b>354</b>	D. Viral Infections . . . . .	370
A. Cutaneous Larva Migrans . . . . .	354	E. Fungal Infections . . . . .	372
B. Cercarial Dermatitis . . . . .	354	F. Bacterial Infections . . . . .	372
C. Subcutaneous Dirofilariasis . . . . .	354	G. Cancers . . . . .	372
D. Onchocerciasis . . . . .	354	H. Dermatoses . . . . .	374
E. Schistosomiasis . . . . .	354	I. Diagnostic Approach . . . . .	374
<b>35.3 Arthropods</b> . . . . .	<b>356</b>	J. Therapy . . . . .	374
A. Pediculosis . . . . .	356	<b>38 Environmental Diseases</b> . . . . .	<b>376</b>
B. Cimicosis . . . . .	356	<b>38.1 Nutritional Disorders</b> . . . . .	<b>376</b>
C. Pulicosis . . . . .	356	A. Nutritional Requirements . . . . .	376
D. Tungiasis . . . . .	356	B. Malnutrition . . . . .	376
E. Myiasis . . . . .	356	C. Eating Disorders . . . . .	376
F. Caterpillar Dermatitis . . . . .	356	D. Zinc . . . . .	376
G. Scabies . . . . .	358	E. Iron . . . . .	378
H. Demodicosis . . . . .	358	F. Copper . . . . .	378
I. Accidental Parasitic Mites . . . . .	358	G. Vitamins . . . . .	378
J. Ticks . . . . .	359	<b>38.2 Photodermatoses</b> . . . . .	<b>380</b>
<b>36 Sexually Transmitted Diseases</b> . . . . .	<b>360</b>	A. Overview . . . . .	380
<b>36.1 Gonorrhea and Chlamydial Infections</b> . . . . .	<b>360</b>	B. Acute Toxic Effects . . . . .	380
A. Gonorrhea . . . . .	360	C. Chronic Harmful Effects . . . . .	380
B. Chlamydial Infections . . . . .	360	D. Sunlight-induced Skin Diseases . . . . .	380
C. Nongonococcal Nonchlamydial Urethritis . . . . .	360	E. Phototoxic and Photoallergic Reactions . . . . .	382
<b>36.2 Syphilis</b> . . . . .	<b>362</b>	F. Idiopathic Disorders . . . . .	382
A. Early Syphilis . . . . .	362	G. Photo-aggravated Diseases . . . . .	382
B. Late Syphilis . . . . .	364	<b>38.3 Heat, Cold, and Other Agents</b> . . . . .	<b>384</b>
C. Congenital Syphilis . . . . .	364	A. Heat . . . . .	384
		B. Cold . . . . .	384
		C. Other Noxious Agents . . . . .	384

## V Appendix

<b>Abbreviations</b> . . . . .	<b>388</b>	<b>Index</b> . . . . .	<b>393</b>
<b>Figure Sources</b> . . . . .	<b>392</b>		